(CercleFinance.com) – DBV Technologies publishes a result for the first half of 2023 with a net loss of 44.8 million dollars, against a loss of 39.7 million a year earlier, due to an increase in operating expenses to 50, 7 million.
Cash and cash equivalents for the biopharmaceutical company – which specializes in allergy treatments – stood at $174 million as of June 30, 2023, a net decrease of $35.2 million over six months.
Separately, DBV reports that the US FDA has provided comments on its two supplemental safety studies, COMFORT Toddlers in infants (one to three years old) and COMFORT Children in children (four to seven years).